| dc.creator |
Covic, Adrian |
|
| dc.creator |
Copur, Sidar |
|
| dc.creator |
Sag, Alan A. |
|
| dc.creator |
AFŞAR, Barış |
|
| dc.creator |
Kanbay, Mehmet |
|
| dc.creator |
Rossignol, Patrick |
|
| dc.date |
2020-06-30T21:00:00Z |
|
| dc.date.accessioned |
2021-01-21T08:05:04Z |
|
| dc.date.available |
2021-01-21T08:05:04Z |
|
| dc.identifier |
4bcf0e31-ac17-4d18-a141-c1d6c0e0841a |
|
| dc.identifier |
10.1007/s11255-020-02563-2 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/4bcf0e31-ac17-4d18-a141-c1d6c0e0841a/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/81383 |
|
| dc.description |
Chronic kidney disease is prevalent, affecting more than one in ten adults. In this population, metabolic acidosis is considered a key underlying pathophysiological feature, tying together bone mineral disorders, sarcopenia, insulin resistance, vascular calcification, pro-inflammatory and pro-thrombotic states. This review aims to address the paucity of literature on alkalinizing agents, a promising treatment option that has known adverse effects. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer |
|
| dc.type |
info:eu-repo/semantics/article |
|